A bipartisan group of U.S. congressional representatives is advocating for the expedited availability of psychedelic therapies for veterans and others experiencing mental health conditions. Representatives Jack Bergman (R-MI) and Lou Correa (D-CA), co-chairs of the Congressional Psychedelics Advancing Therapies Caucus, recently discussed these efforts, highlighting the potential role of substances like psilocybin, ibogaine, and MDMA in addressing significant mental health challenges.
Congressional Advocacy for Psychedelic Therapies
During a recent appearance on CNN, Rep. Correa stated that individuals in his community had reported overcoming alcoholism and drug addiction, and experiencing improvements in mental health conditions, suggesting that psychedelics could offer a promising solution. He noted the high suicide rates among veterans as a critical concern, indicating these therapies might be part of a comprehensive approach to support those struggling.
Rep. Bergman, a Vietnam combat veteran, shared his perspective on the long-term impact of post-traumatic stress, observing that many veterans from his era faced difficulties assimilating back into society. He emphasised the need for new strategies in mental healthcare, stating, “We’ve been doing things the same way forever in mental health and expecting different results.” According to Marijuana Moment, both lawmakers stressed the importance of not only facilitating legal access to psychedelic compounds but also ensuring resources for comprehensive therapeutic support, including trained therapists.
“So we not only need the medicine, we need the therapist trained and ready to go,” Rep. Bergman stated, underscoring the need for a holistic approach to treatment.
Rep. Correa also highlighted that some U.S. military veterans are currently travelling internationally to access these therapies, citing anecdotal accounts of individuals reporting significant improvements after treatments abroad. He urged Congress to advance research and establish appropriate safeguards to ensure patient safety.
Legislative and Federal Initiatives
The bipartisan efforts extend to legislative action. Reps. Bergman and Correa are sponsoring an amendment to a Department of Veterans Affairs (VA) funding bill. This amendment seeks to raise awareness about the potential benefits of psychedelic and other therapies for military veterans by adjusting funding to emphasize research in areas such as oncology, traumatic brain injury care, and psychedelic therapies within the VA’s Medical and Prosthetic Research account.
Furthermore, the two lawmakers led a bipartisan coalition of 32 members of Congress in a letter to federal health officials, urging them to expedite ongoing reviews of psychedelic therapies. This aligns with recent announcements from the FDA and the Department of Health and Human Services (HHS) regarding steps to “accelerate” therapeutic access to psychedelics for patients with serious mental health conditions.
HHS Secretary Robert F. Kennedy Jr. has indicated the administration’s commitment to creating a pathway for access to psychedelic therapy, particularly for military personnel with conditions such as post-traumatic stress disorder (PTSD) and depression, within a “very controlled setting.” VA Secretary Doug Collins also noted an “eye-opening” discussion with Secretary Kennedy regarding the therapeutic potential of psychedelic medicine and expressed openness to government-provided vouchers for veterans seeking these therapies outside the VA system. This builds on earlier discussions, including a U.S. Senate committee hearing last month on a bipartisan bill to promote research into psychedelics, as previously reported by Hemp Gazette.
Advancing Research and Access to Psychedelic Therapies
Congressional lawmakers have also introduced legislation proposing $30 million in annual funding to establish psychedelic-focused “centers for excellence” at VA facilities. These centres would aim to provide novel treatments involving substances like psilocybin, MDMA, and ibogaine. Former U.S. House Speaker Newt Gingrich has described ibogaine as a “significant development” in addressing mental health challenges.
The Congressional Psychedelics Advancing Therapies Caucus remains focused on identifying safe and effective methods to utilise psychedelics to support veterans and others struggling with PTSD, underscoring a cautious yet determined approach to integrating these potential treatments into mainstream care.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
